- Index hide
According to information from the WHO, Until December 22, 2022, more than 650 million confirmed cases of Covid-19 have been detected in the world.
So far, more than 5 million deaths from covid-19 have been reported worldwide.
According to data from the WorldOMeters site, Until December 30, 2022, there have been 5,247 deaths due to covid-19 in China.
Novavax is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the start of Phase 2 for its combined vaccine against Covid-19 and Influenza (COVID-19-Influenza Combination, CIC for its acronym in English).
The dose confirmation trial will evaluate the safety and efficacy (immunogenicity) of different formulations of the combined Covid and Influenza (CIC) vaccine candidates for influenza vaccine in adults 50 to 80 years of age.
“We are encouraged to initiate this trial given the positive results shared earlier this year from our Phase 1/2 trial, the first of its kind to evaluate a combination vaccine against COVID-19 and influenza,” said Stanley C. Erck , Chairman and CEO of Novavax in a Press release.
“We believe that, like influenza, COVID-19 will also be seasonal and that there is room in the market for new alternatives that provide better protection against the impact of influenza, particularly in older adults, and to explore the potential to combine this with protection against COVID.”
According to the official statement from Novavax, The trial, randomized and blind to the participants, will evaluate a combination of the COVID-19 vaccine based on the recombinant protein NVX-CoV2373, a quadrivalent influenza vaccine candidate, and the proprietary saponin-based Matrix-M adjuvant.
The primary and secondary objectives of the study are to assess the safety, tolerability as well as immune responses to various formulations of the CIC and influenza vaccine candidates. The Phase 2 dose confirmation trial will be conducted in two parts and is expected to enroll a total of approximately 2,300 participants at multiple centers in Australia and New Zealand.
Initial trial results are expected in mid-2023. These data will serve as the basis for Phase 3 trials of flu alone and combination COVID-19 vaccine candidates.
Related notes: